Flora Growth (NASDAQ:FLGC – Get Free Report) and NeurAxis (NASDAQ:NRXS – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, valuation and risk.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Flora Growth and NeurAxis, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Flora Growth | 1 | 0 | 0 | 0 | 1.00 |
| NeurAxis | 0 | 1 | 1 | 0 | 2.50 |
NeurAxis has a consensus target price of $13.00, suggesting a potential upside of 126.09%. Given NeurAxis’ stronger consensus rating and higher probable upside, analysts clearly believe NeurAxis is more favorable than Flora Growth.
Risk & Volatility
Flora Growth has a beta of 1.9, meaning that its stock price is 90% more volatile than the S&P 500. Comparatively, NeurAxis has a beta of 1.39, meaning that its stock price is 39% more volatile than the S&P 500.
Insider & Institutional Ownership
36.0% of Flora Growth shares are held by institutional investors. Comparatively, 11.8% of NeurAxis shares are held by institutional investors. 2.3% of Flora Growth shares are held by insiders. Comparatively, 21.1% of NeurAxis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Flora Growth and NeurAxis’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Flora Growth | -32.03% | -64.02% | -34.46% |
| NeurAxis | -492.76% | N/A | -641.25% |
Earnings & Valuation
This table compares Flora Growth and NeurAxis”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Flora Growth | $57.61 million | 0.05 | -$15.91 million | ($32.49) | -0.08 |
| NeurAxis | $6.53 million | 11.05 | -$14.63 million | ($1.06) | -5.42 |
NeurAxis has lower revenue, but higher earnings than Flora Growth. NeurAxis is trading at a lower price-to-earnings ratio than Flora Growth, indicating that it is currently the more affordable of the two stocks.
Summary
NeurAxis beats Flora Growth on 8 of the 14 factors compared between the two stocks.
About Flora Growth
Flora Growth Corp. is a consumer packaged goods and pharmaceutical distribution company focused on cannabis and related wellness products. The company has developed a portfolio of brands serving the medical, adult-use and wellness markets, with products that have included cannabidiol (CBD) and other cannabis-derived offerings, as well as accessories and lifestyle products. Flora’s portfolio has included JustCBD, a CBD-focused brand offering products such as oils, gummies, capsules, topicals and pet products, along with Vessel, which develops vaporization hardware and accessories.
About NeurAxis
NeurAxis, Inc. (NASDAQ: NRXS) is a medical technology company focused on developing and commercializing non-invasive neuromodulation therapies for functional gastrointestinal and other nervous-system-related disorders. The company’s approach is designed to influence neural signaling through targeted electrical stimulation. NeurAxis’s principal product is IB-Stim, a prescription, percutaneous electrical nerve-field stimulation device intended for use in adolescents with functional abdominal pain associated with irritable bowel syndrome and related functional gastrointestinal disorders.
Receive News & Ratings for Flora Growth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flora Growth and related companies with MarketBeat.com's FREE daily email newsletter.
